Gao Yun-Mei, Han Guo-Xiong, Xue Cheng-Hui, Fang Lai-Fu, Li Wen-Qian, Shen Kuo, Xie You-Bang
Department of Hematology, Qinghai Provincial People's Hospital, Xining 810007, Qinghai Province, China.
Health Team, Haidong Detachment, Qinghai Corps, Haidong 810600, Qinghai Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):197-202. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.031.
To explore the pathogenesis of erythrocytosis by detecting the key enzymes of glucose metabolism and glucose transporter in bone marrow erythrocytes of chronic mountain sickness (CMS), and analyzing its correlation with hemoglobin.
Twenty CMS patients hospitalized in Qinghai Provincial People's Hospital from January 2019 to December 2020 were selected as CMS group. Twenty males with leukocyte count > 3.5×10/L who had accepted bone marrow aspiration and had normal result were taken as control group. The mRNA and protein expression of key enzymes and glucose transporter in glucose metabolism in bone marrow CD71 erythrocytes were detected by real time qPCR and Western blot, respectively. Glucose, lactic acid and 2,3-diphosphoglycerate in the bone marrow supernatant and serum were tested by ELISA. The mRNA and protein expression of key enzymes and glucose transporter, glucose, lactic acid and 2,3-diphosphoglycerate of the two groups were compared. Pearson correlation was used to analyze the correlation between key enzymes, glucose transporter in glucose metabolism in bone marrow CD71 erythrocytes and hemoglobin.
The expression of , and mRNA in the CMS group were higher than those in the control group (<0.001), while the expression of , and mRNA were not different. The expression of HK2, GLUT1 and GLUT2 protein in the CMS group were higher than those in the control group (<0.05). The levels of glucose and lactic acid in the bone marrow supernatant and serum in the CMS group were not different from those in the control group, while the level of 2,3-diphosphoglycerate was higher (<0.001). Both HK2 and GLUT2 proteins were positively correlated with hemoglobin (=0.511, 0.717).
CMS patients may increase glycolysis by increasing the expression of HK2, and promote the utilization of glucose through high expression of GLUT1 and GLUT2 to meet the need of energy supply.
